论文部分内容阅读
目的:探讨唑来膦酸联合99Tc-MDP(云克)治疗多发骨转移瘤的临床价值。方法:将40例确诊为肿瘤伴骨转移的病人,随机分为两组。观察组22例,使用唑来膦酸联合99Tc-MDP治疗;对照组18例,单独使用99Tc-MDP治疗,均治疗3周后比较两组治疗前后骨痛的变化情况、骨转移灶的治疗情况及不良反应的发生情况。结果:观察组和对照组的止痛总有效率分别为95.5%和66.7%,差异有统计学意义(P<0.05)。观察组和对照组骨转移灶的治疗总有效率分别为36.3%和27.7%,差异有统计学意义(P<0.05)。此外,两组治疗过程中均偶见不同程度的发热,但不良反应的发生率并无统计学差异(P>0.05)。结论:唑来膦酸联合99Tc-MDP治疗多发骨转移瘤的止痛效果及骨转移灶的疗效显著优于单纯99Tc-MDP治疗,且毒副作用无明显增加。
Objective: To investigate the clinical value of zoledronic acid combined with 99Tc-MDP (Yunke) for the treatment of multiple bone metastases. Methods: Forty patients diagnosed as having cancer metastasis were randomly divided into two groups. 22 cases in the observation group were treated with zoledronic acid combined with 99Tc-MDP. In the control group, 18 cases were treated with 99Tc-MDP alone. Changes of bone pain and bone metastases were compared between the two groups after treatment for 3 weeks And the occurrence of adverse reactions. Results: The total effective rates of pain relief in observation group and control group were 95.5% and 66.7%, respectively, with statistical significance (P <0.05). The total effective rates of treatment of bone metastases in observation group and control group were 36.3% and 27.7%, respectively, with statistical significance (P <0.05). In addition, the incidence of adverse reactions was not significantly different between the two groups (P> 0.05). Conclusion: The analgesic effect of zoledronic acid combined with 99Tc-MDP in the treatment of multiple bone metastases and the therapeutic effect of bone metastases were significantly better than 99Tc-MDP alone, with no obvious increase in the side effects.